Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mesothelin CAR-T cell therapy - Shenzhen BinDeBio

Next Previous
Drug Profile

Mesothelin CAR-T cell therapy - Shenzhen BinDeBio

Alternative Names: CART-meso cells - Shenzhen BinDeBio

Latest Information Update: 28 Aug 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shenzhen BinDeBio
  • Developer Henan Provincial Hospital; Jiangsu Provincial Peoples Hospital; Shenzhen BinDeBio
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Gastric cancer
  • No development reported Pancreatic cancer

Most Recent Events

  • 28 Aug 2021 No recent reports of development identified for clinical-Phase-Unknown development in Pancreatic-cancer(In the elderly, In adults) in China (IV, Infusion)
  • 15 May 2019 Phase-I/II clinical trials in Gastric cancer (Late-stage disease, Second-line therapy or greater, Inoperable/Unresectable) in China (IV) (NCT03941626)
  • 11 Jul 2018 Clinical trials in Pancreatic cancer (In adults, In the elderly) in China (IV) (NCT03638193)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top